4-Aminopyrazolo[3,4-d]pyrimidineCAS# 2380-63-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2380-63-4 | SDF | Download SDF |
PubChem ID | 75420 | Appearance | Powder |
Formula | C5H5N5 | M.Wt | 135 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 1H-pyrazolo[3,4-d]pyrimidin-4-amine | ||
SMILES | C1=NNC2=C1C(=NC=N2)N | ||
Standard InChIKey | LHCPRYRLDOSKHK-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C5H5N5/c6-4-3-1-9-10-5(3)8-2-7-4/h1-2H,(H3,6,7,8,9,10) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
4-Aminopyrazolo[3,4-d]pyrimidine Dilution Calculator
4-Aminopyrazolo[3,4-d]pyrimidine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 7.4074 mL | 37.037 mL | 74.0741 mL | 148.1481 mL | 185.1852 mL |
5 mM | 1.4815 mL | 7.4074 mL | 14.8148 mL | 29.6296 mL | 37.037 mL |
10 mM | 0.7407 mL | 3.7037 mL | 7.4074 mL | 14.8148 mL | 18.5185 mL |
50 mM | 0.1481 mL | 0.7407 mL | 1.4815 mL | 2.963 mL | 3.7037 mL |
100 mM | 0.0741 mL | 0.3704 mL | 0.7407 mL | 1.4815 mL | 1.8519 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Methylprednisolone Sodium Succinate
Catalog No.:BCC5629
CAS No.:2375-03-3
- Rivulobirin E
Catalog No.:BCN5090
CAS No.:237407-59-9
- 4-Amino-3-hydroxybenzoic acid
Catalog No.:BCC8681
CAS No.:2374-03-0
- trans-3'-O-Benzoyl-4'-O-methylkhellactone
Catalog No.:BCN6921
CAS No.:23733-95-1
- trans-Methylkhellactone
Catalog No.:BCN6919
CAS No.:23733-92-8
- 6-Hydroxy-4-Methylcoumarin
Catalog No.:BCC9206
CAS No.:2373-31-1
- Chebulic acid
Catalog No.:BCN3260
CAS No.:23725-05-5
- Nardosinone
Catalog No.:BCN2324
CAS No.:23720-80-1
- Platycoside E
Catalog No.:BCN6385
CAS No.:237068-41-6
- Damascenone
Catalog No.:BCN8355
CAS No.:23696-85-7
- Olaquindox
Catalog No.:BCN2538
CAS No.:23696-28-8
- Boc-Ser(Bzl)-OH
Catalog No.:BCC3442
CAS No.:23680-31-1
- Homovanillyl alcohol
Catalog No.:BCN7173
CAS No.:2380-78-1
- 6-Hydroxyindole
Catalog No.:BCN8310
CAS No.:2380-86-1
- Pogostone
Catalog No.:BCN2696
CAS No.:23800-56-8
- Hinesol
Catalog No.:BCC9232
CAS No.:23811-08-7
- Trichokaurin
Catalog No.:BCN4851
CAS No.:23811-50-9
- Ac-Trp-OEt
Catalog No.:BCC3110
CAS No.:2382-80-1
- Ambroxol HCl
Catalog No.:BCC5067
CAS No.:23828-92-4
- Liensinine perchlorate
Catalog No.:BCN6335
CAS No.:2385-63-9
- Ethyl2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate
Catalog No.:BCC8979
CAS No.:238749-50-3
- Tosedostat (CHR2797)
Catalog No.:BCC2309
CAS No.:238750-77-1
- Zapotinin
Catalog No.:BCC9192
CAS No.:14813-20-8
- Boc-Lys(Z)-OH
Catalog No.:BCC2722
CAS No.:2389-45-9
6-Deoxy-6-[131I]iodo-L-ascorbic acid for the in vivo study of ascorbate: autoradiography, biodistribution in normal and hypolipidemic rats, and in tumor-bearing nude mice.[Pubmed:19881306]
Biol Pharm Bull. 2009 Nov;32(11):1906-11.
Normal female rat distribution studies showed high and specific uptake of 6-deoxy-6-[(131)I]iodo-L-ascorbic acid (6-(131)IAsA) into the adrenal glands, known to highly express the ascorbate sodium-dependent vitamin C transporter-2 (SVCT-2), and the adrenal gland was clearly visualized by whole-body autoradiography. Preinjection of sulfinpyrazone, a known blocker of ascorbate transport, with 6-(131)IAsA resulted in decreased uptake of radioactivity in rat adrenal glands compared to the control group, seemingly illustrating the participation of the SVCT transporter (probably the SVCT-2 subtype) in the uptake process in vivo. 4-Aminopyrazolo[3,4-d]pyrimidine-induced hypolipidemic rats showed a 1.7-fold increase in adrenal uptake of radioactivity at 30 min postinjection of 6-(131)IAsA, compared to the control, with increased adrenal-to-liver and adrenal-to-kidney ratios. To further characterize 6-(131)IAsA for its tumor uptake properties, biodistribution studies were also performed using male nude mice implanted with either Y-1 adrenocortical tumor cells or adrenal medulla-derived PC12 cells. None of these tumors exhibited relevant uptake of 6-(131)IAsA while normal adrenal glands showed high uptake of radioactivity, suggesting that these tumors in this model have only a poor transport capacity for this agent. The present study demonstrates that the use of radioiodinated 6-IAsA may help to obtain information about functional alterations in diseased adrenal glands, but it does not exhibit desirable properties as a tumor-seeking agent for ascorbic acid bioactivity.